Methods and compositions related to arrhythmogenic right ventricular cardiomyopathy (ARVC)
View Patent ↗This disclosure provides the identification of an eight base pair deletion in the 3′-untranslated region (UTR) of the striatin gene that is linked to arrhythmogenic right ventricular cardiomyopathy (ARVC) in Boxer dogs. Also provided are methods for detecting ARVC, methods of breeding Boxer dogs to reduce the prevalence or frequency of ARVC in a population, and methods of screening for a compound useful for treatment of ARVC.
1. A method of detecting arrhythmogenic right ventricular cardiomyopathy (ARVC) in a Boxer dog subject comprising detecting a defect in the striatin gene in a Boxer dog subject, wherein the defect results in reduced striatin expression, wherein detecting a defect in the striatin gene comprises detecting a deletion of an eight base pair sequence of the 3′-untranslated region (UTR) of the striatin gene, wherein the eight base pair sequence corresponds to nucleotides 38-45 of SEQ ID NO: 1, thereby detecting arrhythmogenic right ventricular cardiomyopathy (ARVC) in the Boxer dog subject.
2. The method of claim 1 , wherein detecting the deletion of an eight base pair sequence of the 3′-untranslated region (UTR) of the striatin gene comprises:
isolating DNA from the Boxer dog subject; and
sequencing a region of the DNA including the nucleotide sequence corresponding to nucleotides 38-45 of SEQ ID NO: 1.
3. The method of claim 2 , further comprising amplifying the region of the DNA including the nucleotide sequence corresponding to nucleotides 38-45 of SEQ ID NO: 1, prior to sequencing the region of the DNA.
4. A method of selectively breeding Boxer dogs to decrease the frequency of arrhythmogenic right ventricular cardiomyopathy (ARVC) in a Boxer dog population comprising: identifying Boxer dogs in a breeding population that have a predisposition to arrhythmogenic right ventricular cardiomyopathy (ARVC) by identifying a defect in the striatin gene, wherein the defect results in aberrant striatin expression;
selecting for breeding those Boxer dogs that do not have a predisposition to arrhythmogenic right ventricular cardiomyopathy (ARVC); and breeding only selected Boxer dogs, thereby decreasing the frequency of arrhythmogenic right ventricular cardiomyopathy in the Boxer dog population.
5. The method of claim 4 , wherein detecting a defect in the striatin gene comprises:
measuring striatin gene expression in test samples from the dogs in the breeding population; and
comparing the striatin gene expression in the test samples with a control.
6. The method of claim 5 , wherein measuring striatin gene expression comprises measuring striatin RNA in the test samples.
7. The method of claim 5 , wherein measuring striatin gene expression comprises measuring striatin protein in the test samples.
8. The method of claim 5 , wherein the control is a standard reference value.
9. The method of claim 4 , wherein detecting a defect in the striatin gene comprises detecting a deletion of an eight base pair sequence of the 3′-untranslated region (UTR) of the striatin gene, wherein the eight base pair sequence corresponds to nucleotides 38-45 of SEQ ID NO: 1.
10. The method of claim 9 , wherein detecting the deletion of an eight base pair sequence of the 3′-untranslated region (UTR) of the striatin gene comprises
isolating DNA from the dogs of the population; and
sequencing a region of the DNA including the nucleotide sequence corresponding to nucleotides 38-45 of SEQ ID NO: 1.
11. The method of claim 10 , further comprising amplifying the region of the DNA encompassing the nucleotide sequence corresponding to nucleotides 38-45 of SEQ ID NO: 1, prior to sequencing the region of the DNA.